The rare monogenic arrhythmogenic disorder catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterised by episodic ventricular dysrhythmia triggered by exercise or emotion in individuals without structural cardiac defects. Next generation sequencing has now become more widely accessible and RYR2 in its entirety can be screened relatively easily. This has led to an increase in the number of RYR2 variants being reported in individuals with cardiac dysrhythmia. The majority of RYR2 variants are missense changes that lead to increased channel activity and the rarity of these variants makes it difficult to determine their pathogenicity, thus the majority are classified as being of unknown significance (VUS). We collated RYR2 variants reported in individuals with or suspected of having CPVT and classified them using a statistical method and the ACMG guidelines. Where possible the phenotype associated with each variant was recorded to determine any genotype-phenotype correlations. Recently RYR2 variants have also been shown to cause ventricular arrhythmias by a loss of function mechanism. We used five computational splice prediction tools and an ex vivo splicing assay to investigate whether 329 rare variants in RYR2 from a cohort of individuals undergoing genetic testing for a ventricular arrhythmia alter splicing. Ten RYR2 variants were predicted to disrupt splicing by multiple computational tools. Of these, none altered splicing in an ex vivo splicing assay.
Share this Article
Related Content In Arrhythmia
Foreword – European Journal of Arrhythmia & Electrophysiology. 2021;7(1):1
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):1
Welcome to a new issue of the European Journal of Arrhythmia & Electrophysiology. As the ongoing coronavirus disease 2019 (COVID-19) pandemic continues to provide unprecedented challenges for electrophysiologists and other healthcare providers who manage arrhythmias, we hope you find these topical articles interesting and useful. We begin with an editorial from Professor Hugh Calkins and […]
COVID-19 and Cardiac Arrhythmias
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):33-39 DOI: https://doi.org/10.17925/EJAE.2021.7.1.33
The current outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has developed into a worldwide pandemic affecting millions of lives in one way or another.1 Over the period of 1 year since the disease was first reported from Wuhan, China,2 COVID-19 has infected over 50 million patients and resulted […]
Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia
Heart International. 2021;15(1):2-6 DOI: https://doi.org/10.17925/HI.2021.15.1.2
Paroxysmal supraventricular tachycardia (PSVT) defines a group of cardiac arrhythmias where the underlying mechanism is dependent upon structures at or above the level of the atrioventricular node. The recent PRE-EMPT study retrospectively evaluated health records of over 4.2 million people in the USA, estimating PSVT incidence at 73/100,000, and national prevalence at 168/100,000 (translating into […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!